Neuro-Ophthalmic Manifestations of Adult Polyglucosan Body Disease.

J Neuroophthalmol

Departments of Neurology (AD, NJA, CP, SLG, SNG) and Ophthalmology (CP, SLG), New York University Grossman School of Medicine, New York, New York.

Published: August 2024

Background: Adult polyglucosan body disease (APBD) is caused by a deficiency in glycogen branching enzyme that leads to polyglucosan accumulation in multiple organs. It has a progressive clinical course with prominent neurologic manifestations. We aim to describe the neuro-ophthalmic manifestations of APBD.

Methods: This is a case series of 3 individuals with genetically proven APBD. Written informed consent was provided by the brothers. We also performed a literature review on the current state of knowledge on APBD through PubMed.

Results: Brother 1 developed gait imbalance and length-dependent polyneuropathy in his 40s followed by progressive urinary symptoms in his 50s. He reported diplopia and blurry vision in his 60s. Neuro-ophthalmic assessment revealed bilateral optic neuropathy, convergence insufficiency, and a right fourth nerve palsy. Genetic testing showed a homozygous pathogenic variant in GBE1 c.986A>C p.Tyr329Ser. Brother 2 developed progressive urinary symptoms in his 40s that were followed by cognitive deficits, length-dependent polyneuropathy, and lower extremity weakness in his 50s and 60s. He reported blurred vision, and neuro-ophthalmic evaluation revealed bilateral optic neuropathy. Genetic testing revealed the same variant as Brother 1, GBE1 c.986A>C p.Tyr329Ser. Brother 3 developed progressive urinary urgency and lower extremity weakness in his 50s followed by a length-dependent polyneuropathy in his 60s. He reported diplopia and blurry vision in his 70s. Neuro-ophthalmic assessment revealed bilateral optic neuropathy and convergence insufficiency. Genetic testing revealed the same variant as Brothers 1 and 2, GBE1 c.986A>C p.Tyr329Ser.

Conclusions: There is an array of afferent and efferent neuro-ophthalmic manifestations in APBD. Neuro-ophthalmic evaluation is crucial in evaluating and treating patients with APBD, particularly in those with visual dysfunction.

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNO.0000000000002186DOI Listing

Publication Analysis

Top Keywords

neuro-ophthalmic manifestations
12
brother developed
12
length-dependent polyneuropathy
12
progressive urinary
12
revealed bilateral
12
bilateral optic
12
optic neuropathy
12
genetic testing
12
gbe1 c986a>c
12
adult polyglucosan
8

Similar Publications

[Research progress on the manifestations prevention and treatment of immune-related adverse events in the neuro-ophthalmic efferent system related to immune checkpoint inhibitors].

Zhonghua Yan Ke Za Zhi

January 2025

Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing100730, China.

Immune checkpoint inhibitors (ICI), as a new type of targeted therapeutic drugs, have demonstrated durable efficacy in cancer treatment. However, some patients receiving ICI treatment may be affected by immune-related adverse events (irAE). Compared with irAE in skin tissues, gastrointestinal system, etc.

View Article and Find Full Text PDF
Article Synopsis
  • This text emphasizes the need for ophthalmologists and oncologists to better understand ocular immune-related adverse events (irAEs) caused by PD-1 inhibitors for early detection and management.
  • A review of 70 case reports found that melanoma and lung cancer were the most common malignancies associated with these adverse events, primarily involving the PD-1 inhibitors pembrolizumab and nivolumab.
  • The most frequent ocular complications included uveitis and myasthenia gravis, typically managed with steroids, while severe cases may necessitate stopping the PD-1 inhibitors, highlighting the importance of collaboration between specialties for effective patient care.
View Article and Find Full Text PDF

Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review.

Biomedicines

November 2024

Department of Surgery, Division of Ophthalmology, University of Sherbrooke, Sherbrooke, QC J1G 2E8, Canada.

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, offering significant improvements in patient survival across various malignancies. However, their use is associated with a broad spectrum of immune-related adverse events (irAEs), including those affecting the eye and its surrounding structures, collectively termed ocular irAEs (OirAEs). Although rare, OirAEs (e.

View Article and Find Full Text PDF

Leukodystrophies are a group of rare genetic diseases that primarily affect the white matter of the central nervous system. The broad spectrum of metabolic and pathological causes leads to manifestations at any age, most often in childhood and adolescence, and a variety of symptoms. Leukodystrophies are usually progressive, resulting in severe disabilities and premature death.

View Article and Find Full Text PDF

Carotid-cavernous fistulas (CCFs) are pathologic, arteriovenous communications between the carotid artery and cavernous sinus. They cause various complex neuro-ophthalmic symptoms by shunting the flow of arterial blood into the venous system. In this study, a systematic review is conducted on the neuro-ophthalmic presentations associated with CCFs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!